Cover Image
Market Research Report

Acute Respiratory Distress Syndrome - Pipeline Review, H1 2019

Published by Global Markets Direct Product code 192441
Published Content info 111 Pages
Delivery time: 1-2 business days
Price
Back to Top
Acute Respiratory Distress Syndrome - Pipeline Review, H1 2019
Published: February 1, 2019 Content info: 111 Pages
Description

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Respiratory Distress Syndrome - Pipeline Review, H1 2019, provides an overview of the Acute Respiratory Distress Syndrome (Respiratory) pipeline landscape.

Acute respiratory distress syndrome (ARDS) occurs when fluid fills up the air sacs in lungs. This leads to low oxygen levels in the blood. Common causes of ARDS include sepsis, inhalation of harmful substances, severe pneumonia and head or chest injury. Signs and symptoms of ARDS include severe shortness of breath, labored and unusually rapid breathing, low blood pressure and confusion and extreme tiredness.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Respiratory Distress Syndrome - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Respiratory Distress Syndrome (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Acute Respiratory Distress Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 7, 11 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Acute Respiratory Distress Syndrome (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acute Respiratory Distress Syndrome (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acute Respiratory Distress Syndrome (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC11086IDB

Table of Contents

  • Introduction
  • Acute Respiratory Distress Syndrome - Overview
  • Acute Respiratory Distress Syndrome - Therapeutics Development
  • Acute Respiratory Distress Syndrome - Therapeutics Assessment
  • Acute Respiratory Distress Syndrome - Companies Involved in Therapeutics Development
  • Acute Respiratory Distress Syndrome - Drug Profiles
  • Acute Respiratory Distress Syndrome - Dormant Projects
  • Acute Respiratory Distress Syndrome - Discontinued Products
  • Acute Respiratory Distress Syndrome - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Acute Respiratory Distress Syndrome, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Acute Respiratory Distress Syndrome - Pipeline by Athersys Inc, H1 2019
  • Acute Respiratory Distress Syndrome - Pipeline by Bayer AG, H1 2019
  • Acute Respiratory Distress Syndrome - Pipeline by Cells for Cells SA, H1 2019
  • Acute Respiratory Distress Syndrome - Pipeline by Commence Bio Inc, H1 2019
  • Acute Respiratory Distress Syndrome - Pipeline by CompleGen Inc, H1 2019
  • Acute Respiratory Distress Syndrome - Pipeline by Cynata Therapeutics Ltd, H1 2019
  • Acute Respiratory Distress Syndrome - Pipeline by Faron Pharmaceuticals Oy, H1 2019
  • Acute Respiratory Distress Syndrome - Pipeline by GlaxoSmithKline Plc, H1 2019
  • Acute Respiratory Distress Syndrome - Pipeline by Hydra Biosciences Inc, H1 2019
  • Acute Respiratory Distress Syndrome - Pipeline by Meridigen Biotech Co Ltd, H1 2019
  • Acute Respiratory Distress Syndrome - Pipeline by PaxVax Inc, H1 2019
  • Acute Respiratory Distress Syndrome - Pipeline by ProMetic Life Sciences Inc, H1 2019
  • Acute Respiratory Distress Syndrome - Pipeline by Savara Inc, H1 2019
  • Acute Respiratory Distress Syndrome - Pipeline by SolAeroMed Inc, H1 2019
  • Acute Respiratory Distress Syndrome - Pipeline by Windtree Therapeutics Inc, H1 2019
  • Acute Respiratory Distress Syndrome - Dormant Projects, H1 2019
  • Acute Respiratory Distress Syndrome - Dormant Projects, H1 2019 (Contd..1), H1 2019
  • Acute Respiratory Distress Syndrome - Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development for Acute Respiratory Distress Syndrome, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products by Top 10 Targets, H1 2019
  • Number of Products by Stage and Top 10 Targets, H1 2019
  • Number of Products by Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Top 10 Molecule Types, H1 2019
  • Number of Products by Stage and Top 10 Molecule Types, H1 2019
Back to Top